ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $762,083 | $626,793 | $894,619 |
| - Cash | $112,672 | $112,765 | $49,865 | $74,293 |
| + Debt | $0 | $98 | $138 | $176 |
| Enterprise Value | – | $649,416 | $577,066 | $820,502 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$34,978 | -$31,399 | -$66,772 | -$23,705 |
| % Margin | – | – | – | – |
| Net Income | -$34,978 | -$31,399 | -$64,387 | -$20,633 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.83 | -0.9 | -1.9 | -0.61 |
| % Growth | 7.8% | 52.6% | -211.5% | – |
| Operating Cash Flow | -$35,798 | -$26,124 | -$68,008 | -$16,152 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$35,798 | -$26,124 | -$68,008 | -$16,152 |